Follow-up outcomes of Mindfulness-Based Cognitive Therapy (MBCT) for patients with chronic, treatment-resistant depression.
Study Goal
The researchers aimed to evaluate the long-term outcomes of Mindfulness-Based Cognitive Therapy (MBCT) for chronically, treatment-resistant depressed patients over a 6-month follow-up period and identify predictors of treatment outcomes.
Results Summary
MBCT led to sustained improvements in depressive symptoms, quality of life, rumination, mindfulness skills, and self-compassion over 6 months, with remission rates increasing further during follow-up. Higher baseline rumination predicted better outcomes, while other factors (e.g., duration of depression, treatment resistance, childhood trauma) did not influence results.
Population
Chronically, treatment-resistant depressed outpatients (N = 106).
Effective Dosage
Not specified
Duration
6-month follow-up (intervention duration not explicitly stated)
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Mindfulness-based cognitive therapy (MBCT) | no change | depressive symptoms | chronically, treatment-resistant depressed outpatients | - | consolidated during follow-up | #1 |
Mindfulness-based cognitive therapy (MBCT) | no change | quality of life | chronically, treatment-resistant depressed outpatients | - | consolidated during follow-up | #2 |
Mindfulness-based cognitive therapy (MBCT) | no change | rumination | chronically, treatment-resistant depressed outpatients | - | consolidated during follow-up | #3 |
Mindfulness-based cognitive therapy (MBCT) | no change | mindfulness skills | chronically, treatment-resistant depressed outpatients | - | consolidated during follow-up | #4 |
Mindfulness-based cognitive therapy (MBCT) | no change | self-compassion | chronically, treatment-resistant depressed outpatients | - | consolidated during follow-up | #5 |
Mindfulness-based cognitive therapy (MBCT) | increase | remission rates | chronically, treatment-resistant depressed outpatients | - | even further increased over the course of follow-up | #6 |
- | decrease | depressive symptoms | participants with high levels of rumination | - | predicted lower | #7 |
- | decrease | quality of life | participants with high levels of rumination | - | predicted lower | #8 |
- | no change | duration of the current episode | chronically, treatment-resistant depressed patients | - | did not predict treatment outcome | #9 |
- | no change | level of treatment-resistance | chronically, treatment-resistant depressed patients | - | did not predict treatment outcome | #10 |
- | no change | childhood trauma | chronically, treatment-resistant depressed patients | - | did not predict treatment outcome | #11 |
- | no change | baseline levels of mindfulness skills | chronically, treatment-resistant depressed patients | - | did not predict treatment outcome | #12 |
- | no change | baseline levels of self-compassion | chronically, treatment-resistant depressed patients | - | did not predict treatment outcome | #13 |
BACKGROUND: Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment for depression. The current study focused on the long-term outcomes of MBCT for chronically, treatment-resistant depressed patients during a 6-months follow-up period. Additionally, predictors of treatment outcomes were explored. METHOD: The outcomes of MBCT on depressive symptoms, remission rates, quality of life, rumination, mindfulness skills and self-compassion were investigated in a cohort of chronically, treatment-resistant depressed outpatients (N = 106), who had taken part in an RCT comparing MBCT with treatment-as-usual (TAU). Measures were assessed pre-MBCT, post-MBCT, at 3-months follow-up, and at 6-months follow-up. RESULTS: Results of linear mixed effect models and Bayesian repeated measures ANOVA's reveal that depressive symptoms, quality of life, rumination, mindfulness skills and self-compassion consolidated during follow-up. Remission rates even further increased over the course of follow-up. When controlling for symptoms at baseline, higher baseline levels of rumination predicted lower depressive symptoms and quality of life at 6-month follow-up. No other predictors (i.e. duration of current depressive episode, level of treatment-resistance, childhood trauma, mindfulness skills, self-compassion) were found. LIMITATIONS: All participants received MBCT, therefore time or other non-specific effects might have influenced the results and replication studies including a control conditions are needed. CONCLUSIONS: Results indicate that the clinical benefits of MBCT for chronically, treatment-resistant depressed patients persist up to 6 months after completing MBCT. Duration of the current episode, level of treatment-resistance, childhood trauma and baseline levels of mindfulness skills and self-compassion did not predict treatment outcome. When controlling for baseline depressive symptoms participants with high levels of rumination seem to benefit more; however more research is needed. TRIAL REGISTRY: Dutch Trial Registry, number NTR4843.